Home >  Oncology MDTV >  Oncology Shorts >  Commonly used prostate...

Commonly used prostate cancer treatment rewires engine of prostate tumors: Research

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-16 03:45 GMT   |   Update On 2022-09-16 03:45 GMT
Advertisement
Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. These findings have been published in Nature Communications.
Male hormones function as fuel, turning on the androgen receptor that acts as the engine of prostate cancer cells. The researchers wanted to understand what was present in these tumors, to begin with and what happened after tumors started to grow on enzalutamide treatment. They recruited patients to a longitudinal study to obtain metastatic biopsies before enzalutamide treatment and at the time the tumor became resistant to treatment. His team collected serial biopsies from 21 patients, enabling them to understand the workarounds in the tumor from each patient.
Advertisement
When they compared the baseline sample to the progression sample from the same patient, most tumors showed no significant gene expression changes.In three of the 21 cases, the team saw a profound shift in the wiring—or gene expression program—of the tumors.
But they found that in 15 percent of cases, the tumors also became fuel-independent for another reason.Also three tumors converted to become double negative prostate cancer—akin to an electric vehicle.Although the baseline tumors appeared similar under the microscope, the research team identified specific genes that were highly expressed in those that eventually became double negative prostate cancer.
This result suggests that certain tumors exist in a hybrid state, initially dependent on fuel but at risk for becoming a fuel-independent double negative prostate cancer during enzalutamide treatment.
Reference:
Joshi Alumkal et al,Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity,Nature Communications,DOI 10.1038/s41467-022-32701-6
Full View
Tags:    
Article Source : Nature Communications,

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Rectal Cancer - Dr. Poulami Basu

How COVID-19 May Awaken Dormant Breast Cancer Cells? Study Provides Insights

Study Reveals Artificial Sweetener May Weaken Cancer Immunotherapy

Medical Bulletin 31/July/2025

Study Reveals Cannabis Use Disorder Linked to Three Times Higher Risk of Oral Cancer

3 Out of 5 Liver Cancer Cases Preventable, Says Lancet Commission; Calls for Urgent Focus on Hepatitis, Alcohol, and Obesity

This Sugar Substitute May Help Kill Cancer Cells: Study Suggests

Can a Simple Breath Test Detect Blood Cancer? Study Finds Out